Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2,068 | $1,461 | $1,440 | $0 |
| % Growth | 41.5% | 1.5% | – | – |
| Cost of Goods Sold | $1,345 | $58,895 | $56,357 | $482 |
| Gross Profit | $723 | -$57,434 | -$54,917 | -$482 |
| % Margin | 35% | -3,931.1% | -3,813.7% | – |
| R&D Expenses | $68,758 | $58,895 | $56,357 | $17,191 |
| G&A Expenses | $31,197 | $30,600 | $27,098 | $20,744 |
| SG&A Expenses | $31,197 | $30,600 | $27,098 | $20,744 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $762 | -$1,775 | $469 | -$31,715 |
| Operating Expenses | $99,955 | $89,495 | $83,455 | $37,935 |
| Operating Income | -$99,232 | -$88,034 | -$82,015 | -$37,935 |
| % Margin | -4,798.5% | -6,025.6% | -5,695.5% | – |
| Other Income/Exp. Net | $5,122 | -$1,415 | $850 | -$37,787 |
| Pre-Tax Income | -$94,110 | -$89,449 | -$81,165 | -$75,722 |
| Tax Expense | $787 | -$1,837 | -$118 | $2,611 |
| Net Income | -$94,897 | -$87,612 | -$81,047 | -$78,333 |
| % Margin | -4,588.8% | -5,996.7% | -5,628.3% | – |
| EPS | -1.45 | -2 | -1.9 | -3.56 |
| % Growth | 27.5% | -5.3% | 46.6% | – |
| EPS Diluted | -1.45 | -2 | -1.9 | -3.56 |
| Weighted Avg Shares Out | 65,612 | 43,749 | 42,599 | 22,033 |
| Weighted Avg Shares Out Dil | 65,612 | 43,749 | 42,599 | 22,033 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,526 | $2,161 | $381 | $327 |
| Interest Expense | $5,166 | $1,801 | $0 | $327 |
| Depreciation & Amortization | $1,345 | $386 | $634 | $6,881 |
| EBITDA | -$87,599 | -$87,262 | -$81,381 | -$31,054 |
| % Margin | -4,235.9% | -5,972.8% | -5,651.5% | – |